Healthcare Industry Insights

Wednesday, 12 February 2020

Clinical Trial Supplies Market Trends, Segmentation and Future Scope

The global Clinical Trial Supplies Market is expected to reach USD 3.3 billion by 2025, according to a new report by Grand View Research, Inc. The market is expected to witness growth at 7.3% CAGR owing to Increasing volume of clinical trial studies coupled with the growing complexity in conduction of these trials are the primary driver of the industry. Furthermore, geographic expansion and development of Information Technology (IT) to facilitate higher integration and smooth performance of activities are other vitally impacting parameters. Over the next eight years, the clinical trials and pharmaceutical industry is anticipated to continue steady growth, thereby promoting the high requirement of clinical trial supplies.

U.S and Canada are home to majority of clinical trials which are conducted in this region. No language barrier is one of the major factor for the preference of this region for majority of clinical trials, as English language is widely spoken in this region. Major CRO’s and biopharmaceutical companies have their hub in this region and with advancement in technology the demand for efficient supplies are increasing and the region is expected to dominate the clinical trial supplies market over the forecast period.

Browse Details of Report @
http://www.grandviewresearch.com/industry-analysis/clinical-trial-supplies-market

Further Key Findings From the Study Suggest:

On the basis of clinical phase, the market is anticipated to be dominated by Phase III in 2025. The presence of large number of molecule estimated to reach Phase III by 2020 is the primary factor responsible for this prediction.
By services, storage and distribution is anticipated to witness the fastest growth at a CAGR of over 7.0%.
Key end-users of this industry are pharmaceuticals, and biologics. Biologics are expected to witness fastest growth owing to the increasing research in the field of genetics and biotechnology such as development of nanoparticle based drug delivery systems.
In terms of therapeutic use or clinical indication, oncology dominates the market. The highest research activity as of 2016 is being performed for this indication, which in turn is expected to drive the market.
Few of the industry players include Movianto GmbH, Thermo Fischer Scientific, Sharp Packaging Services, Catalent Pharma Solution, Biocair International Ltd., PCI Services, Almac Group Ltd, and Patheon Inc. Other players present in the market space include Clinigen Group Plc, Merck Serono, and Chimerix.

About Grand View Research

Grand View Research, Inc. is a U.S. based market research and consulting company, registered in the State of California and headquartered in San Francisco. The company provides syndicated research reports, customized research reports, and consulting services. To help clients make informed business decisions, we offer market intelligence studies ensuring relevant and fact-based research across a range of industries, from technology to chemicals, materials and healthcare.

Contact:
Sherry James
Corporate Sales Specialist, USA
Grand View Research, Inc
Phone: 1-415- 349-0058
Toll Free: 1-888- 202-9519
Email: sales@grandviewresearch.com
For More Information: https://www.grandviewresearch.com

Tuesday, 11 February 2020

Healthcare Satellite Connectivity Market: Emerging Trends and Growth Drivers

The global Healthcare Satellite Connectivity Market size is expected to reach USD 10.1 billion by 2025, at a CAGR of 7.1% according to a new report by Grand View Research, Inc. Globally, rising adoption of eHealth & other services and growing usage of technology platforms by hospitals & medical providers are crucial factors that boost the market growth.

Several governments are working toward providing improved basic medical facilities in rural areas with a key focus on improving connectivity infrastructure in healthcare and provision of enhanced care services. Some of the players in satellite connectivity are also undertaking projects in order to enhance healthcare provisions in underserved regions. For instance, Satellite Applications Catapult, a satellite technology company has collaborated with the Cayetano Heredia University in Northern Peru to improve medical services in the remote areas of Amazonia by providing enhanced connectivity solutions for mobile healthcare facilities along with the usage of eHealth and mHealth solutions.

Furthermore, the increasing pressure on medical facilities due to reduced budgets, ageing population, increasing number of patients with chronic conditions, shortage of adequately trained medical staff & doctors, lack of proper infrastructure in rural areas, and growing demand for real-time distance learning, telemedicine, and video services of higher quality are some of the other factors contributing to the growing adoption of satellite technology in healthcare. According to the Federal Communications Commission, rural areas are underserved by terrestrial broadband services as compared to urban areas. In 2016, 20 % did not have access to services at even 4 Mbps/1 Mbps and 31 % lacked access to 10 Mbps/1 Mbps broadband services. Provision of high-speed satellite technology would be a key solution to eliminate this geographic barrier and offer superior medical facilities.

Browse Details of Report @
http://www.grandviewresearch.com/industry-analysis/healthcare-satellite-connectivity-market

Further key findings from the report suggest:

The system & software segment held majority of market share amongst the component segment in 2016 due to growing demand for data analytics in the healthcare sector
eHealth was the dominating application segment in 2016 due to growing government initiatives promoting integration of technology in healthcare
Hospitals & Clinics were the dominating end-use segment in 2016 with a share of 65.3% owing to the rising adoption of technology platforms for delivering medical care
Fixed mobile services held majority of the market share in 2016 in the connectivity segment with a share of 83%
The Asia Pacific market is expected to witness lucrative growth over the forecast period owing to the improving infrastructure and increasing patient pool

Key players include Inmarsat plc; Hughes Network Systems LLC, SES S.A., X2nSat, Expedition Communications, Globalstar, Eutelsat

About Grand View Research

Contact:
Sherry James
Corporate Sales Specialist, USA
Grand View Research, Inc
Phone: 1-415- 349-0058
Toll Free: 1-888- 202-9519
Email: sales@grandviewresearch.com
For More Information: https://www.grandviewresearch.com

Orthopedic Bone Cement Market – Industry Analysis and Outlook Report, 2025

The global Orthopedic Bone Cement Market size is expected to reach USD 1.1 billion by 2025, according to a new report by Grand View Research, Inc. Growing number of orthopedic surgeries is one of the key factors expected to drive revenue growth in coming few years.

Orthopedic bone cement helps support and anchor artificial joints and fractured bones. It works by filling the empty space between the bone and an implant, which anchors the joint. This in turn provides stability and elasticity to the joints. Bone cement was introduced in 1940s and has been widely used by physicians since then. The increasing number of orthopedic surgeries globally is expected to boost demand for the cement in near future. As per Australian Society of Orthopedic Surgeons, the number of musculoskeletal surgeries had increased by 18% between 2007 and 2011 and is expected to witness continuous growth, which in turn is expected to create growth opportunity for the manufacturers.

Ageing population is another important factor responsible for increasing demand for bone cement. Old people are more susceptible to fractures and associated injury and often require joint replacement surgery. This cement provides a better alternative to screws and wires, which can create discomfort to the patients. According to a United Nations report in 2015, the population of people aged 60 years and above is projected to grow by 56% and is expected to reach 1.4 billion by 2030. This in turn is expected to bolster the patient pool for joint replacement surgeries and in turn propel revenue growth for bone cement market over the forecast period.

Browse Details of Report @

http://www.grandviewresearch.com/industry-analysis/orthopedic-bone-cement-market

Further Key Findings From the Report Suggest:

The global orthopedic bone cement market size was estimated at USD 692.8 million in 2016 and is expected to grow at a CAGR of 5.9% from 2017 to 2025
Hospital emerged as the largest end-use segment in 2015 and is estimated to generate revenue over USD 501.2 million by 2025
Ambulatory surgical centers segment was USD 150.2 million in 2016 and is anticipated to witness fastest growth over the next 9 years
The Asia Pacific region is projected to witness substantial growth over the next decade owing to various developments across major economies in the region. This regional market is expected to grow at a CAGR of 6.7% from 2017 to 2025
Some of the key players including Stryker Corporation; Zimmer Biomet; DePuy Synthes; and Smith & Nephew, Inc. dominated the global market.

About Grand View Research

Cartilage Regeneration Market Size is Estimated to Value $6.7 Billion By 2025

The global Cartilage Repair/Regeneration Market size is expected to reach USD 6.7 billion by 2025, according to a new report by Grand View Research, Inc. The market is expected to witness lucrative growth over the forecast period, owing to increasing prevalence of bone & joint disorders, such as Osteoarthritis (OA), rising geriatric population, and surge in number of accidents & related injuries across the globe.

Increasing number of road accidents worldwide are causing bone and joint injuries, which is anticipated to fuel the demand for cartilage repair products over the forecast period. For instance, as per data published by the World Health Organization (WHO) in November 2016, approximately 1.25 million people die each year in road accidents worldwide, owing to the influence of alcohol & reckless driving, use of mobile phone, and other associated factors such as bad weather conditions & improper road construction.

Around 30.0 million children and adolescents participate in youth sports in the U.S each year. This increase in sports activity increases incidents of injuries in athletes, which in turn propels demand for cartilage repair products. According to research data by the American Orthopaedic Society for Sports Medicine, over 3.5 million athletes receive medical treatment due to sports injuries each year.

Browse Details of Report @
http://www.grandviewresearch.com/industry-analysis/cartilage-repair-regeneration-market

Further Key Findings From the Study Suggest:

The cell-based segment held a profitable revenue share in 2016 and is anticipated to grow at a significant rate over the forecast period owing to rising preference for autologous chondrocyte transplantation for surgical treatment of damaged articular cartilage (chondral and osteochondral lesions)
The hyaline cartilage segment is anticipated to witness the fastest growth during the forecast period due to high susceptibility of damage to hyaline cartilage in case cartilage-related injuries and increase in sport injuries
Owing to the extensive use of microfracture techniques during cartilage repair surgeries, the intrinsic repair stimulus segment dominated the market in 2016
Increasing prevalence of OA and rise in accident-related injuries are anticipated to support the growth of knee cartilage repair segment
North America is expected to dominate the cartilage repair market during the forecast period, owing to the rising prevalence of bone & joint disorders, increase in number of accidents & injuries, and growing geriatric population in the region are expected to spur the cartilage regeneration market growth.
Some of the key players of market are Zimmer Biomet; Stryker Corporation; DePuy Synthes; Smith & Nephew plc; Vericel Corporation; Osiris Therapeutics Inc.; B. Braun Melsungen AG; Anika Therapeutics, Inc.; Arthrex, Inc.; and Collagen Solutions Plc.

About Grand View Research

Monday, 10 February 2020

Hyaluronic Acid Raw Material Market is Projected to Observe 6.7% CAGR till 2024

The global Hyaluronic Acid Raw Material Market size is expected to reach a value of USD 7.25 billion by 2024, according to a new report by Grand View Research, Inc. The increasing use of hyaluronic acid in various medical applications, such as osteoarthritis, wound healing, postoperative adhesion, tympanic membrane repair, tumor diagnosis, fracture healing, and soft tissue repair is expected to fuel the market growth over the forecast period.

The orthopedics segment dominated the overall market in 2015 with the highest revenue generation. The increasing geriatric population base, rising incidence of osteoarthritis, and growing adoption of viscosupplements in the treatments contribute to the large market share of this segment. Furthermore, the drug delivery segment is projected to be the fastest growing over the forecast period with a significantly higher CAGR. The increasing R&D activities focusing on targeted drug delivery systems and growing usage of hyaluronic acid in anti-cancer drug delivery is expected to contribute to the market growth.

The increasing women population of age 35 to 65 years across the globe engenders a greater demand for anti-aging cosmetic and aesthetic treatments. Owing to the distinctive viscoelastic and moisturizing properties coupled with lower toxicity levels offered by hyaluronic acid-based products, the demand for this polymer in dermal fillers as well as in the treatment of vesicoureteral reflux is expected to experience growth. Thus, it is anticipated that the need for such products will serve as a high impact driver for the hyaluronic acid products over the forecast period. Based on the statistics of the International Society of Aesthetic Plastic Surgery in 2014, there were approximately 20 million cosmetic procedures performed globally, of which nearly 13.5% of the procedures were HA-based non-surgical procedures.

Some of the top countries recording a majority of the aesthetic treatments in 2014 were the U.S., Brazil, Japan, South Korea, Mexico, Germany, France, and Colombia. Medical tourism for cosmetic surgery in the U.S. plays a very important role in aiding the uptake of HA-based products and procedures, which is expected to drive the market in the coming few years.

Browse Details of Report @ http://www.grandviewresearch.com/industry-analysis/hyaluronic-acid-ha-raw-material-market

Further Key Findings From the Study Suggest:

In 2015, orthopedics was the largest application segment, owing to rising prevalence and incidence of osteoarthritis
The introduction of FDA-approved hyaluronic acid-based viscosupplements such as ORTHOVISC and MONOVISC is expected to boost usage over the next 8 years
Some of the key market players are Salix Pharmaceuticals; ALLERGAN; Lifecore Biomedical, LLC; Shiseido Co., Ltd.; Anika Therapeutics, Inc.; Smith & Nephew; Maruha Nichiro Corporation; Ferring B.V.; SEIKAGAKU CORPORATION; Genzyme Corporation; F. Hoffmann-La Roche Ltd., Contipro a.s.; Zimmer Biomet; and others

About Grand View Research

Structural Heart Devices Market by Medtronic, ST. JUDE MEDICAL, Boston Scientific Corporation and Others

The global Structural Heart Devices Market size is expected to reach USD 9.1 billion by 2025, based on a new report by Grand View Research, Inc. The market is expected to witness an exponential growth over the next 8 years due to the rapid increase in cardiovascular conditions and increasing power of healthcare expenditure.

The defects are mostly present at birth, thereby directly affecting the under-5 mortality rate of a country. Therefore, rigorous actions are being undertaken by various government bodies across the globe to increase access to treatment. The Centers for Disease Control and Prevention have a public action plan to efficient management of cardiac conditions.

In addition, other organizations are working on improving the scenario for structural heart diseases treatment. For instance, in November 2016, the Cardiovascular Research Foundation (CRF) announced a launch of a journal focusing on diagnosis and treatment of structural heart defects. It was titled Structural Heart: The Journal of the Heart Team and is expected to be launched in May 2017. This is expected to trigger research & development activities along with capital invested in this field, resulting in technological advancements.

Browse Details of Report @
http://www.grandviewresearch.com/industry-analysis/structural-heart-devices-market

Further key findings from the study suggest:

Surgical Aortic Valve Replacement (SAVR) dominated the market in 2016, closely followed by Transcatheter Aortic Valve Replacement (TAVR). It can be attributed to the longest presence of the technique in the treatment regimen of aortic stenosis
Left Atrial Appendage Closure (LAAC) is anticipated to be one of the fastest growing segment owing to the minimally invasive nature of the procedure. It also helps in reduction of risk of stroke, thus is projected to have a higher demand
Geographically, North America held the largest structural heart devices market share in 2016 and is expected to maintain its position during the forecast period. High prevalence of cognitive heart diseases is the key reason for this dominance. Moreover, the mandatory CCHD screening for newborns imposed by the Centers for Disease Control and Prevention (CDC) and American Academy of Pediatrics (AAP) in September 2014 also contributes to the growth in this region
Asia Pacific is also expected to witness a rapid growth over the forecast period. The improved access and capability for treatments in this region is the key reason for this growth
Some of the key players are Medtronic, ST. JUDE MEDICAL, Boston Scientific Corporation, CardioKinetix, Comed BV, Edwards Lifesciences Corporation, LivaNova PLC, Abbott Laboratories, JenaValve Technology, Inc., and Biomerics

About Grand View Research

Friday, 7 February 2020

Contrast Media Agents Market Trends, Growth Opportunities and Overview

The global Contrast Media Agents Market size is estimated to reach USD 6.93 billion by 2027 and is expected to witness a CAGR of 3.5%, according to a new report by Grand View Research, Inc. Increasing burden of chronic diseases is driving diagnostic imaging procedure volumes as well as utilization of contrast media agents. Also, competitive strategies deployed by key companies are expected to support market growth. Among these, Guerbet, GE, and Bayer were the forerunners with top-selling drugs in their respective portfolios and securing more than 50% of the overall market share in 2017.

Bayer has to its advantage the leading MRI agent, Gadavist/Gadovist, a macrocyclic gadolinium agent. While, Guerbet recently jumped positions in the market since it joined forces with Mallinckrodt. The acquisition has led to a streamlined portfolio of MRI and x-ray/CT contrast media that now hold center position in this market. GE competes with Omnipaque and Visipaque as part of its suite of offerings.Along with increasing chronic disease incidence and prevalence trends, rising demand and use of diagnostic imaging modalities is driven by the advancements in the underlying technology.

These range across equipment and administration technology. Equipment advances include innovation, such as syringeless injectors, which help in achieving greater accuracy in dose delivery, shorter examination time, and higher patient throughput. Regionally, North America is leading the contrast media agents market with significant share. Presence of well-established healthcare infrastructure, availability of advanced technologies, and recent launch of new contrast media agents for specific indications account for the revenue share of this region.

Browse Details of Report @
https://www.grandviewresearch.com/industry-analysis/contrast-media-contrast-agents-market

Further key findings from the study suggest:

In 2017, iodinated contrast agents registered maximum sales due to the high penetration of contrast media agents in x-ray and CT procedures driven by availability of non-ionic stable iodinated agents for improved diagnosis
X-ray/CT modality technique was the largest segment in 2017, in terms of sales revenue, due to its wide acceptance and utilization
Cardiovascular Diseases (CVDs) applications segment is expected to witness the fastest growth over the forecast period due to label extensions for ultrasound and X-ray/CT contrast agents in U.S. For instance, Lumason was recently approved by the U.S. FDA for use in liver ultrasonography
North America captured the highest revenue in 2017 owing to presence of well-established healthcare infrastructure and availability of advanced technology
Europe and Asia followed in terms of revenue in 2017, attributable to high penetration of contrast agents, usage of diagnostic imaging modalities, and growing presence of domestic companies in Asia
Key companies in the contrast media agents market are Bayer AG, GE Healthcare; Guerbet LLC; Lantheus Medical Imaging, Inc.; Bracco Diagnostics, Inc.; Daiichi Sankyo Co. Ltd.; and Fuji Pharma Co. Ltd.

About Grand View Research